Kornimate/medical-research-clean huggingface dataset:
china peace 5p-hf study

Conditions: Heart Failure

Summary: the investigators will consecutively recruit 5000 patients hospitalized for heart failure (hf) from 50 hospitals across china and follow them up for one year, describe treatment patterns during hospitalization and the follow-ups, examine patients recovery trajectory after hf, and identify targets for care quality improvement.

this study will consecutively enroll patients with hf as the primary reason for hospitalization in 50 hospitals scattered all over china. participants will be interviewed at baseline (i.e., during the index hospitalization for hf), and at 1, 6, and 12 months following hospital discharge. during the follow-up period, participants will be instructed to return to the hospital for interviews by site investigators. telephone follow-ups will be conducted only when in-person interviews are not feasible. at baseline, participants will be interviewed to collect detailed information about on demographics, socioeconomic status, cardiovascular risk factors, clinical characteristics, treatments, in-hospital outcomes, general and disease-specific quality of life, function and mental status; during the follow-ups, the investigators will collect information about clinical outcomes events, long-term treatments, function, quality of life, symptoms, and medical care during the recovery period. the investigators will collect blood and urine samples during index hospitalization and the follow-ups. this study will examine a series of factors that may affect patients' recovery after hf. practical guidelines, quality evaluative system, and risk model will be established based on the findings, to improve patient outcomes in the future.

Eligibility criteria:
* inclusion criteria: 1. patients with heart failure as the primary reason for hospitalization, including both new-onset hf or decompensation of chronic hf 2. aged 18 years or above * exclusion criteria: 1. patients who have enrolled in this study 2. patients who usually do not live in the city/county where the index hospital locates 3. patients who are unable to complete interviews due to severe conditions, mental illness, or communication difficulties.

Keywords: heart failure prospective cohort
prospective monocentric registry of patients undergoing vitamin d treatment at san raffaele hospital

Conditions: Hypovitaminosis D

Summary: the endocrinology unit of the irccs san raffaele hospital is dedicated to establishing a prospective single-center registry with data from patients undergoing vitamin d supplementation, initiating their first visit to the outpatient unit until december 2029. 1000 patients will be enrolled, aligning with the unit's recent patient influx for hypovitaminosis d. the registry's goal is to assess the epidemiological trend, identify risk factors, and evaluate the diagnostic and therapeutic clinical management strategies for hypovitaminosis d. it will involve collecting clinical, laboratory, and historical data during outpatient visits, adhering to the standard diagnostic and therapeutic protocols for endocrine-metabolic diseases. this data collection is expected to continue for a duration of ten years.


Eligibility criteria:
inclusion criteria: * adult men and women (age ≥ 18 years) regardless of fertility status and pregnancy/breastfeeding conditions * vitamin d supplementation, with any formulation and dosage * signing of informed consent exclusion criteria: * patients unable to understand and sign informed consent.
inspiratory muscle training in heart failure

Conditions: Chronic Heart Failure

Summary: the aim of this study is to investigate the potential effects of inspiratory muscle training on cardiovascular, respiratory, physical, and psychosocial functions in patients with heart failure.

heart failure is a syndrome that leads to decreased cardiac output, inflammation, increased catabolism, and prolonged immobilization, causing inspiratory muscle weakness. cardiac rehabilitation is a well-known treatment approach in heart failure however, the participation rate in cardiac rehabilitation is low. therefore, inspiratory muscle training may serve as an alternative approach in patients with heart failure. patients will be randomly allocated into the inspiratory muscle training group and control group. the inspiratory muscle training (imt) group will carry out imt sessions three days per week for 8 weeks by using an inspiratory threshold loading device. each session will consist of seven cycles including 2 min of breathing on an inspiratory loading device followed by 1 min of rest and will last 21 min. imt will be performed at the tolerable maximum load for each 2-min work interval and will be progressively increased over the 8 weeks. the control group will perform unloaded imt by using an inspiratory threshold loading device during all training sessions. data will be collected before and after the treatment by a masked outcome assessor.

Eligibility criteria:
inclusion criteria: * diagnosis of heart failure with reduced ejection fraction * clinically stable * functional class ii-iii according to the new york heart association functional classification * having inspiratory muscle weakness (mip\<70%) * volunteer to participation exclusion criteria: * congenital heart disease * severe valvular heart disease * cardiac device such as implantable cardioverter defibrillator or cardiac resynchronization therapy * neurological disease * conditions that may limit the physical mobility
moxifloxacin i.v. in the treatment of complicated intra-abdominal infection (ciai)

Conditions: Secondary Peritonitis; Abscess, Intra-Abdominal

Summary: this study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. patients documented must suffer from a ciai and take at least one dose of moxifloxacin infusion.the primary objective is to define the types of ciai infections that require moxifloxacin i.v. therapy in china.


Eligibility criteria:
inclusion criteria: * patients at least 18 years of age with a diagnosis of ciai treated with moxifloxacin infusion with/without sequential tablet treatment can be included into the study. the local moxifloxacin product information must be considered. exclusion criteria: * contraindications stated in the local moxifloxacin product information. warnings and precautions, stated in the local moxifloxacin product information must be considered as potential exclusion criteria.

Keywords: moxifloxacin, ciai non-interventional
the effect of transcutaneous posterior tibial nerve stimulation in patients with fibromyalgia

Conditions: Fibromyalgia

Summary: this study aimed to investigate the effectiveness of posterior tibial nerve stimulation (ptns) in reducing pain, improving quality of life, and decreasing disease severity in patients with fibromyalgia.

this prospective, single-blind, randomized controlled trial included female patients newly diagnosed with fibromyalgia who had started duloxetine treatment (30 mg/day). patients who met the inclusion criteria and agreed to participate in the study were randomized (1:1) into two groups. group 1 (ptns+duloxetine) underwent six sessions of posterior tibial nerve stimulation, twice weekly, 3-4 days apart, in addition to duloxetine (30 mg/day). group 2 (duloxetine) received duloxetine only (30 mg/day). randomization was performed manually, with assignments placed in opaque and sequentially numbered envelopes by off-site researchers who were not involved in patient care or follow-up. outcome measures were assessed by two investigators who were blinded to each patient's group. the participants and nerve stimulators were not blinded to the group allocation. patients were briefed to not disclose which group they were in during the assessment process.patients in the study group received six sessions of posterior tibial nerve stimulation, twice weekly, 3-4 days apart, in addition to duloxetine; the controls received duloxetine only. the patients were evaluated three times (at baseline, 1st month, and 3rd month). pain was evaluated using a numeric rating scale, the short-form mcgill pain questionnaire, and quality of life with a 36-item short-form health survey (sf-36). patient functional status and disease severity were evaluated using the fibromyalgia impact questionnaire (fiq).

Eligibility criteria:
inclusion criteria: * female patients aged between 18 and 65 years, newly diagnosed according to the american rheumatology association 2016 revised fms diagnostic criteria * patients who come regularly to sessions for posterior tibial nerve stimulation. exclusion criteria: * history of fracture/musculoskeletal surgery in the last 3 years * inflammatory joint disease, or neurological disease/neurological deficit with examination * receiving medical treatment for polyneuropathy * contraindications to pns (pacemaker, epilepsy, diminished skin sensation in the area to be applied).

Keywords: chronic pain electric stimulation therapy fibromyalgia quality of life small fiber neuropathy
muscle energy technique with or without first rib mobilization in adhesive capsulitis

Conditions: Adhesive Capsulitis

Summary: this study will be a randomized control trial. study will be conducted in 40 patients in the age range 40-70 years, which will be selected by using non proability convenient sampling technique. subjects will be divided in 2 groups. group a will receive first rib mobilization along with mets and conventional treatment, group b will receive mets and conventional physical therapy treatment only. treatment will be given thrice per week for 3 weeks. data will be collected pre and post treatment, for data collection numeric pain rating scale, shoulder pain and disability index (spadi) will be used. joint range of motion will be measured using goniometer. after collection data from defined study setting, data will be entered and analyzed at riphah international university, lahore.

adhesive capsulitis, also known as "frozen shoulder," is a common condition of the shoulder defined as a pathologic process in which contracture of the gleno-humeral capsule is a hallmark. clinically, it presents as pain, stiffness, and dysfunction of the affected shoulder. adhesive capsulitis is thought to afflict between 2 and 5% of the general population, with women affected more frequently than men. individuals of middle age are most often affected, typically during the 5th to 7th decades of life. muscle energy techniques is a manual therapy that uses the gentle muscle contractions to relax and lengthen muscles and normalize joint motion. it is a class of soft tissue osteopathic manipulation consisting of isometric contraction designed to improve musculoskeletal function and reduce pain. the application of met relaxes and improves biomechanics and result in improving functional ability. although conventional physical therapy treatment are used to treat frozen shoulder and effectiveness of muscle energy technique is proven, but the effect of first rib mobilization and met has not been studied.

Eligibility criteria:
inclusion criteria: * age between 40-70 years * gender (both male and female) * subjects with adhesive capsulitis stage (ii and iii) exclusion criteria: * previous surgery on affected shoulder * recent trauma to shoulder * fracture

Keywords: muscle energy technique, first rib mobilization
efficacy and safety evaluation in recurrent wheezing attacks

Conditions: Bronchospasm; Bronchiolitis; Bronchospasm; Bronchitis

Summary: the study will be conducted in two hospitals of the same geographic area. it will be included children \<3-years-old with recurrent wheezing attacks, confirmed by the review of the medical records, in the previous 12 months or a shorter time for those younger than one year.

this randomized, double-blind, placebo-controlled, parallel-group study will included 120 children \<3 years old with ≥3 episodes of wheezing during the previous year. they will receive active treatment or placebo for six months. the main outcome will be the number of wheezing attacks during one year. other outcomes were duration and severity of wheezing attacks , symptom and medication scores, and use of health resources.

Eligibility criteria:
inclusion criteria: * subjects whose parents /legal representative have given written informed consent. * both gender * subject up to 36 months of age. * subjects with recurrent bronchospasms (wheezing attacks); 3 or more exacerbations in the last 12 months exclusion criteria: * subjects whose parents/legal representative have not given written informed consent. * subjects out of aged range * subjects with malignancies or chemotherapy treatment * subjects included in another clinical trial in the last 12 months. * subject in immunosuppressive or immunostimulatory treatment * subjects who have received iv gamma globulin in the past 12 months. * subjects diagnosed with candidiasis or fungal recurrent infections. * subjects diagnosed with malabsorption syndrome * subjects with clinical allergy to common aeroallergens in the geographical area. * subjects with hepatitis virus infections, hiv and tuberculosis

Keywords: vaccine bronchospasm
data on the impact of different treatment on the quality of life of patients with acute and chronic hemorrhoid disease

Conditions: Hemorrhoids

Summary: the program is aimed at obtaining data on the impact of the method and type of treatment on the quality of life of patients with acute or chronic hemorrhoids with option of conservative treatment with detralex

changes in the quality of life of patients suffering from acute or chronic hemorrhoids within 1 month after presenting to a doctor, in general population and in specific demographic and clinical groups. the program included patients who presented to a doctor for acute or chronic hemorrhoids. all the treatment was fully compliant with the conventional clinical practice, instructions for medical use of drugs and a specific clinical situation. the standard parameters usually evaluated in patients with hemorrhoids were studied during the program. in addition, at the first visit to the doctor and at the end of the study, the patient filled out an sf-36 questionnaire for assessing the qol the general population of patients included in the program, the following three groups of patients were considered: * group 1, with only conservative (medical) therapy during the study; * group 2, with conservative (medical) therapy and additional minimally invasive procedure during the study (no surgery); * group 3, with conservative (medical) therapy and additional surgery for hemorrhoids during the study.

Eligibility criteria:
inclusion criteria: 1. age over 18 years; 2. providing written information to a patient about inclusion in the program, and his/her consent to participate in it, 3. absence of conditions requiring urgent medical care and not related to hemorrhoids; 4. the patient was diagnosed with: * acute hemorrhoids; * exacerbation of chronic hemorrhoids; * chronic hemorrhoids exclusion criteria: 1. the patient is consulting for an urgent issue not related to hemorrhoids; 2. the presence of severe systemic diseases; 3. pregnancy; 4. inability to understand the meaning of the program and follow the doctor's recommendations 5. patients with inflammatory bowel diseases 6. patients with concomitant diseases of the anal canal 7. patients taking anticoagulants; 8. patients with previous anorectal surgeries, including hemorrhoidectomy or excision of anal fistula.
3d time-of-flight magnetic resonance angiography in hemodialysis patients with arteriovenous fistula

Conditions: Magnetic Resonance Angiography; Hemodialysis; Arteriovenous Fistula Stenosis

Summary: this study is aimed to assess the value of three-dimensional time-of-flight magnetic resonance angiography (3d-tof-mra) in hemodialysis patients with occlusive disease in arteriovenous fistula (avf). all participants will receive 3d-tof-mra and ultrasound to detect the stenosis degree of avf.

the principle of 3d-tof-mra is based on the "flow effect" of mr. in the ge sequence of mra imaging, the effect of rf pulses makes the protons in the stationary tissue in the active layer in a saturated state, and the longitudinal magnetization disappears. when the inflow blood appears, its protons are in an unsaturated state and have a high degree of longitudinal magnetization. in this way, a clear difference is formed between saturated tissue and unsaturated flowing blood to display blood vessels. therefore as a non-invasive and safe method for diagnosing vascular diseases, 3d-tof-mra is used widely in cerebrovascular diseases. however, there are currently no studies using 3d-tof-mra to diagnose arteriovenous fistula (avf) stenosis in hemodialysis patients. this project plans to use 3d-tof-mra to detect avf stenosis in hemodialysis patients to provide a safe and effective diagnostic method for patients with end-stage renal failure.

Eligibility criteria:
inclusion criteria: * hemodialysis patients suspected of occlusive disease in arteriovenous fistula (avf); * persistent edema of the limb with the fistula; * decreased pulse or fremitus in anastomotic astium * increase in venous pressure; blood flow at the access of less than 200 ml/min; exclusion criteria: * previous endovascular recanalization with stent or graft placement; * contraindications to magnetic resonance imaging (mri) examination; * platelet(plt)\ 1.5; 4. important organ function failure or other serious illness; 5. allergic to antiplatelet drug, anticoagulant drug, anaesthetic drug and contrast material.
lenvatinib, tislelizumab combined with gemcitabine and cisplatin (gplet) in the treatment of advanced cholangiocarcinoma

Conditions: Advanced Cholangiocarcinoma

Summary: cholangiocarcinoma (cca) is a heterogeneous group of cancers arising from the epithelial cells of bile ducts. because of highly aggressive malignancy, most of the patients are diagnosed at an advanced stage and lose the chance to undergo surgery. as more effective and novel chemotherapy, targeted therapies, and immunotherapy become available, multiple treatments can be chosen for the patients with advanced cca. cytotoxic cell death during tumor chemotherapy triggers antigen release and induces strong anti-tumor effects of t cells. tyrosine kinase inhibitors (tki) can reduce the expression of pd-l1 and inhibit treg cell infiltration, and together with immune checkpoint inhibitors, they can relieve tumor immunosuppressive microenvironment. therefore, the study aims to investigate the safety and efficacy of lenvatinib, tislelizumab combined with gemcitabine plus cisplatin (gplet) in the treatment of advanced cholangiocarcinoma.


Eligibility criteria:
inclusion criteria: * histologically proven, unresectable advanced or metastatic cholangiocarcinoma patients. * expected survival period \> 12 weeks. * the world health organization (who) / ecog physical status (ps) was 0 or 1. * there was at least one target lesion that matched the recist 1.1 criteria at baseline. * not previously received immunotherapy, including but not limited to ctla 4, pd-l1 or/and pd-1 inhibitors. * adequate organ and bone marrow function, defined as follows: hemoglobin (hb)≥9.0g/dl; neutrophils (anc) ≥ 1.5\* 10\^9/l; platelet (pt) ≥ 50\*10\^9/l; alt≤2.5×uln（normal upper limit); ast≤2.5×uln. * voluntary participation and signing of informed consent. exclusion criteria: * active or previously documented autoimmune disease or inflammatory disease. * uncontrolled complications. * history of other primary malignancies. * active infection. * women who are pregnant or breastfeeding. * patients with severe allergic history or specific constitution. * researchers consider it inappropriate to participate in the test.

Keywords: lenvatinib tislelizumab gemcitabine and cisplatin
a study evaluating efficacy and safety of ym150 compared to enoxaparin in subjects undergoing hip replacement surgery

Conditions: Venous Thromboembolism; Arthroplasty, Replacement, Hip

Summary: the purpose of this study is to evaluate the efficacy and safety of various doses of ym150 (the experimental drug) compared to enoxaparin in the prevention of venous thromboembolism in patients that are undergoing elective hip replacement surgery.


Eligibility criteria:
inclusion criteria: * subject is scheduled for elective hip replacement surgery exclusion criteria: * subject has active bleeding or any condition associated with increased risk of bleeding * subject has had major trauma or surgery within 3 months before planned hip replacement surgery or requires major surgery or other invasive procedures with potential for uncontrolled bleeding during the study * subject has had an mi or stroke within 3 months before planned hip replacement surgery

Keywords: elective hip replacement surgery factor xa venous thromboembolism thrombosis anticoagulants prevention ym150
resolution of primary immune defect in 22q11.2 deletion syndrome

Conditions: Immune Defect; 22q11.2 Deletion Syndrome

Summary: * evaluate about age of resolution in immune defect in 22q11.2 deletion syndrome * incidence of immunodeficiencies in 22q11.2 deletion syndrome

22q11.2 deletion syndrome is the most common for microdeletion syndrome. the incidence is about 1:4000 of live birth. clinical features in this syndrome are vary which consist of conotruncal cardiac anomalies, developmental disabilities, palatal anomalies, speech delay, hypocalcemia, characteristic facial features and immunodeficiencies. the most common type of immunodeficiencies is t cell defect that associated with thymic hypoplasia. in the present time, the investigators don't know about the resolution of immune defect in this syndrome.

Eligibility criteria:
inclusion criteria: * 22q11.2 deletion syndrome patients in allergy and immunology clinic, genetic clinic, cardio clinic, genetic clinic and development clinic exclusion criteria: * loss follow up in 22q11.2 deletion syndrome patients or incomplete medical record
camrelizumab combined with or without apatinib and sox of neoadjuvant treatment for gastric cancer

Conditions: Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Summary: this study is a multicenter, randomized, uncontrolled clinical trial to evaluate the efficacy and safety of camrelizumab combined with or without apatinib and sox of neoadjuvant treatment for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.


Eligibility criteria:
inclusion criteria: 1. has previously untreated localized gastric or gej adenocarcinoma as defined by t3-4n+m0 (according to ajcc 8th edition) ; 2. plans to proceed to surgery after completion of neoadjuvant therapy; 3. has an eastern cooperative oncology group (ecog) performance status score of 0 to 1. 4. has adequate organ function. 5. female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose, and be willing to use a highly effective method of contraception during the study and for 2 months after the last dose of carrelizumab or 8 weeks after apatinib or 6 months after chemotherapy drugs, whichever is longer. 6. male subjects whose partners are women of reproductive age should be surgically sterilized or agree to use highly effective methods of contraception during the study and for 2 months after the last administration of carrilizumab or 8 weeks after apatinib or 3 months after chemotherapy drugs, whichever is longer. sperm donation is not allowed during the study. exclusion criteria: 1. known her2 positive; 2. known peritoneal metastasis or positive peritoneal cytology (cy1p0) or t4b (according to ajcc 8th edition); 3. previous or concurrent malignancies, except for cured basal cell carcinoma of skin, carcinoma in situ of cervix, and carcinoma in situ of breast; 4. uncontrolled hypertension ( systolic ≥140 mmhg or diastolic ≥90 mmhg despite antihypertensive therapy)； 5. known hypersensitivity to any of the study drugs or excipients; 6. known hereditary or acquired bleeding and thrombotic tendencies (e.g. hemophiliacs, coagulation disorders, thrombocytopenia, etc.); 7. congenital or acquired immune deficiency (e.g. hiv infected)